Global Growth Hormone Deficiency Market - 2022-2029

Global Growth Hormone Deficiency Market - 2022-2029

Market Overview

Growth Hormone Deficiency Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.4% during the forecast period (2022-2029).

Growth hormone deficiency (GHD) is a rare endocrine disorder that occurs due to impaired secretion of somatropin, a peptide growth hormone (GH) from the pituitary gland responsible for growth and cell reproduction. GHD is classified into three categories: congenital, acquired, or idiopathic. Congenital GHD is present at the time of birth and can be caused either by genetic mutations or structural abnormality in the brain. Acquired GHD occurs in later stages of life due to trauma, infection, or tumors, among many other causes. Idiopathic GHD has unknown or undiagnosed causes. Children with GHD have retarded growth and sometimes delayed puberty. The predominant symptom of GHD in children is abnormally shorter height than other children of the same age with or without compromise in cognitive intelligence. At the same time, GHD may lead to fatigue, tiredness, anxiety, and depression in adults. In addition to height, growth hormone regulates carbohydrate metabolism, protein metabolism, and fat metabolism. Without treatment, GHD in adults can affect the patient’s working capacity, mental alertness, and memory. GHD can also have adverse effects on body composition, like increased body fat, an increase in total cholesterol, and a rise in osteoporosis.

The over secretion of GH leads to gigantism, and its deficiency causes dwarfism. Recombinant DNA technology is used in the manufacturing of human GH drugs.

Market Dynamics

The market is driven by increased incidences of GHD, the introduction of technologically advanced drugs with improved patient compliance, and increased awareness of the disease.

The increasing product approvals and interventional clinical studies drive global market growth.

The ample amount of interventional active clinical studies is fueling the global market growth. For instance, according to Clinical trials.gov, 6 interventional clinical studies are active and are expected to be completed during the forecast period. Furthermore, the new product and market approvals are fueling global market growth. For instance, on August 26, 2021, the FDA approved the first once-weekly formulation of somatropin Lonapegsomatropin-acid injection (Skytrofa) from Ascendis Pharma. Also, on February 15, 2022, the European Commission granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone by Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. Moreover, on August 28, 2020, The U.S. Food and Drug Administration approved Sogroya (somapacitan) by Novo Nordisk for adults with growth hormone deficiency. Sogroya is the first human growth hormone (hGH) therapy that adult patients only take once a week by injection under the skin.

The costly GHD treatment is restraining global market growth.

However, the high cost of treatment for GHD is the only reason that is expected to restrain the market growth over the forecast period.

Industry analysis

The global growth hormone deficiency report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, pipeline analysis Etc.

Segment Analysis

Growth hormone therapy is expected to have a greater grasp on the growth hormone deficiency market during the forecast period (2022-2029).

Growth hormone therapy dominated the global market in 2021 and is estimated to maintain dominance throughout the forecast period (2022-2029). The increasing cases of Adult Growth Hormone Deficiency (AGHD) are due to increased diseases such as pituitary tumors and neuropsychiatric-cognitive, neuromuscular, cardiovascular, skeletal, and metabolic abnormalities. The Society for Endocrinology estimates that adult-onset GH deficiency is approximately 1 in 10,000 of the adult UK population. If adults with childhood-onset GH deficiency are also considered, the prevalence may be as high as 3 in 10,000 of the adult population; this equates to approximately 12,600 adult patients with GH deficiency in England and Wales. Surgery is rarely an option for GHD; most of these disorders can be reversed with growth hormone therapy.

Geographical Analysis

North America is expected to command the global growth hormone deficiency market.

North America is assumed to account for the largest market share in the forecast period (2022-2029) due to the affordability of costly medicine, a robust pipeline, and the local presence of key market players. According to Boston Children’s Hospital, about one in 4,000 to 10,000 children have growth hormone deficiency in the US. Approximately 50,000 adults have a growth hormone deficiency, with about 6,000 new adult patients diagnosed yearly. Moreover, a few key market players, such as Pfizer, EMD Serono, Inc., Eli Lilly and Company and Genentech, Inc., which holds a majority of the market, are US based, ensuring the dominance of North America over the global growth hormone deficiency market.

Competitive Landscape

Sandoz International GmbH, Sanofi-Aventis, Pfizer, Novo Nordisk A/S, Teva Pharmaceutical Industries Limited, Ranbaxy, EMD Serono, Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Ferring Holding SA, Genentech, Inc., Merck & Co., Inc., Ipsen, GeneScience Pharmaceuticals Co., Ltd., and Roche Holdings, Inc. are some of the prominent key players in the market. Most of the companies in the market are trying to produce novel drugs for better treatment of GHD. These companies have strong pipeline drugs that can change the course of treatment within the next five years. For instance, Also, on January 31, 2020, Sandoz completed the acquisition of Aspen’s Japanese operations. Also, on April 16, 2021, Sanofi acquired Kiadis.

Pfizer

Overview:

Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.

Product Portfolio:

The product portfolio of Pfizer for growth hormone deficiency has GENOTROPIN (somatropin), NGENLA (somatrogon), Etc.

The global growth hormone deficiency report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.